GSK’s gonorrhoea drug hits major target in late-stage trial

British drugmaker GSK said its oral drug to treat gonorrhoea has achieved a key goal of staying ahead of existing combination drugs in late-stage trials. GSK said the study showed that the efficacy and safety of gepotidacin was no worse than the combination treatment of the muscle-injectable antibiotic ceftriaxone and the antibiotic tablet azithromycin.

Share This Post: